ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) Director Christopher D. Maggiore acquired 7,200 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was purchased at an average cost of $3.53 per share, with a total value of $25,416.00. Following the acquisition, the director now directly owns 810,305 shares of the company’s stock, valued at approximately $2,860,376.65. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
ZIVO Bioscience Stock Up 1.3 %
ZIVO opened at $3.18 on Wednesday. ZIVO Bioscience, Inc. has a fifty-two week low of $2.37 and a fifty-two week high of $6.98. The company has a fifty day moving average of $3.73 and a two-hundred day moving average of $3.58.
Institutional Trading of ZIVO Bioscience
ZIVO Bioscience Company Profile
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.